Pharma & Biotech Mergers & Acquisitions News
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Today's issue
Refine Search
Latest Mergers & Acquisitions News & Features
Pharmaceutical
Swiss pharma giant Novartis today announced an upgrade to its mid-term guidance, in advance of its Meet Novartis Management event for investors and analysts in London. 21 November 2024
Biotechnology
Aizen Therapeutics, an AI-driven biotech headquartered in San Diego, has officially launched from stealth mode, introducing its drug discovery platform, DaX. 21 November 2024
Biotechnology
Massachusetts, USA-based firm VBI Vaccines has initiated a nationwide voluntary recall of PreHevbrio (hepatitis B vaccine), as it proceeds with bankruptcy and the shutdown of its operations. 19 November 2024
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Biotechnology
Last week saw US pharma major AbbVie release disappointing Phase II trial results on its emraclidine in schizophrenia, which benefited Bristol Myers Squibb. Also on the research front, Germany’s Merck KGaA and Abbisko’s pimicotinib showed positive results in tenosynovial giant cell tumor (TGCT). M&A news saw German BioNTech punting $800 million upfront to acquire China based oncology focused Biotheus. Also of note, US drugmaker Halozyme Therapeutics made an unsolicited takeover bid for Evotec, valuing the German firm, at around 2 billion euros. 17 November 2024
Biosimilars
South Korean biosimilars company Celltrion today announced its acquisition of iQone Healthcare Switzerland a specialty pharmaceutical company focused on distribution, sales, and marketing in Switzerland. 15 November 2024
Biotechnology
Shares of German drug discovery company Evotec leapt 20% to 10.33 euros this morning on the revelation that the USA’s Halozyme Therapeutics has submitted a non-binding proposal to acquire Evotec for 11.00 euros per share in cash, implying a fully-diluted equity value of around 2.0 billion euros ($2.12 billion). 15 November 2024
Biotechnology
BeiGene has announced plans to rebrand as BeOne Medicines, a move the cancer specialist says reflects its commitment to fighting cancer through collaboration. 15 November 2024
Pharmaceutical
Life science investor Syncona has announced the launch of its newest portfolio company, Slingshot Therapeutics, through the Syncona Accelerator initiative. 14 November 2024
Biotechnology
Although it is seeing a downturn in sales and profits, German biotech BioNTech is continuing to acquire assets with the cash pile it made through the covid pandemic, notably iis Comirnaty vaccine that was developed with Pfizer (NYSE: PFE). 13 November 2024
Biotechnology
Trace Neuroscience, a newly launched biopharma based in San Francisco, aims to advance treatments for neurodegenerative diseases, starting with amyotrophic lateral sclerosis (ALS). 12 November 2024
Biotechnology
AlloVir has entered into a definitive agreement to merge with biopharma company Kalaris Therapeutics. 8 November 2024
Pharmaceutical
European regulators will decide by December 6 whether Novo Holdings, the controlling shareholder of Danish pharma giant Novo Nordisk, can finalize its $16.5 billion acquisition of contract drug manufacturer Catalent. 5 November 2024
Biotechnology
California, USA-based biotech Nektar Therapeutics’ shares closed up more than 8% at $1.33 yesterday after it announced the sale of its only manufacturing facility. 5 November 2024
Pharmaceutical
Pharmaceutical M&A came back with a bang during October, after a quiet September. 5 November 2024
Pharmaceutical
US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co. Also of note, Lexicon’s type I diabetes drug Zynquista faced a Food and Drug Administration (FDA) advisory committee review that resulted in largely negative vote against recommendation. 3 November 2024
Biotechnology
Maryland, USA–based glycobiology specialist GlycoMimetics has entered into an acquisition agreement with Crescent Biopharma, a privately held biotechnology company advancing a pipeline of oncology therapeutics designed to treat solid tumors. 30 October 2024
Biotechnology
German drugmaker Dr Falk Pharma GmbH today announced completion of the acquisition of Kynos Therapeutics, a clinical stage biopharmaceutical company focusing on the development of novel KMO inhibitors for acute and chronic inflammatory diseases. 29 October 2024
Biotechnology
US Pharma major AbbVie has reached a definitive agreement to acquire Aliada Therapeutics, a biotech advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. 29 October 2024
Biotechnology
Ottimo Pharma, a biotech founded by Medicxi in 2020, has emerged from stealth mode with an executive team packed with prominent industry leaders. 28 October 2024
Biotechnology
Shares in Beijing-based Sinovac Biotech are up 1% after morning trading in New York, following the news that Sinobioway Consortium has upped its offer to buy the firm, from $7 to $8 per share. 10 August 2017
Generics
A two-tier manufacturing market and forecast increased acquisitions by Indian companies, along with a notable improvement in the international reputation of Indian made pharmaceuticals have been identified in a new report for CPhI titled: 2017 India Pharma Market Report. 10 August 2017
Pharmaceutical
A new leading drugmaker is to be established in Russia as a result of the recently announced merging of the pharmaceutical assets of Russian state corporation Rostec and local pharmaceutical producer Marathon Group. 9 August 2017
Pharmaceutical
US specialty biopharmaceutical firm Mallinckrodt is to acquire InfaCare Pharmaceutical in a deal that could add up to $425 million. 4 August 2017
Biotechnology
Bristol-Myers Squibb says it will acquire IFM Therapeutics, a venture-backed biotech focused on developing therapies that modulate novel targets in the innate immune system to treat cancer, autoimmunity and inflammatory disorders. 4 August 2017
Generics
The Cabinet Committee on Economic Affairs of India (CCEA) has decided to block Shanghai Fosun Pharmaceutical’s 8.5 billion yuan ($1.3 billion) takeover of the Indian drugmaker Gland Pharma, according to reports. 3 August 2017
Pharmaceutical
USA-based Collidion has entered into a definitive agreement to acquire an 80% equity stake in Plex Pharmaceuticals (formerly known as CalAsia) in exchange for an undisclosed amount of cash and contributing a novel drug asset under development. 2 August 2017
Pharmaceutical
There was a summer slowdown in the pace of pharma and biotech mergers and acquisitions during July, and it is likely to continue into August. 2 August 2017
Biotechnology
Germany's Evotec has announced that it is to buy US contract research organization (CRO) Aptuit in a $300 million deal. 31 July 2017
Pharmaceutical
Israel-based NeuroDerm says it has signed a definitive agreement under which Japan’s Mitsubishi Tanabe Pharma will acquire US-listed central nervous system disorders specialist NeuroDerm for $39 per share in cash. 25 July 2017
Generics
The executive and the supervisory boards of German generic drugs maker Stada Arzneimittel (SAZ: Xetra) today published their reasoned joint statement on the renewed voluntary public takeover offer by Nidda Healthcare Holding, the acquiring company of Bain Capital and Cinven, for all outstanding shares in Stada. 25 July 2017
Generics
Baxter International and Claris Lifesciences Limited have agreed to divest two types of pharmaceutical products to settle Federal Trade Commission charges that Baxter’s proposed $625 million acquisition of Claris Injectables business of the Indian parent company is anticompetitive. 21 July 2017
Biotechnology
UK-based Tissue Regenix has announced the conditional acquisition of CellRight Technologies, a US regenerative medicine business. 21 July 2017
Biotechnology
The pharmaceutical industry is one of the UK’s great success stories, writes Michael Jewell, healthcare partner at Cavendish Corporate Finance, in an Expert View piece on how the sector could see an increase in deal-making as Brexit looms. 20 July 2017
Pharmaceutical
Beleaguered Canadian firm Valeant Pharmaceuticals International (TSX: VRX) has entered into an agreement to sell its Obagi Medical Products business for $190 million in cash to Haitong International Zhonghua Finance Acquisition Fund I. 18 July 2017
Pharmaceutical
Political news last week focused on the US Republicans in the Senate revealing their latest proposals to javascript:void(0);repeal and replace Obamacare and in Europe the perceived plight of the pharmaceutical industry and patient access to medicines in the event of Britain’s unorderly withdrawal from the European Union. On the company front, there was news of Sanofi’s acquisition of US vaccines maker Protein Biosciences, developments on Amicus Therapeutics’ Fabry disease drug, a Complete Response Letter for Ocular Therapeutix, Ocular Therapeutix, and the rumored departure of AstraZeneca’s chief executive Pascal Soriot. 16 July 2017
Generics
Medicure, a specialty pharma focused on the development and commercialization of therapeutics for the US hospital market, has exercised an option to snap up additional interests in Apicore, the New Jersey-based API developer and manufacturer. 11 July 2017
Generics
Bain Capital and Cinven, through their Nidda Healthcare unit, have been cleared by German regulators to submit a renewed binding voluntary public takeover offer for all outstanding shares of Stada Arzneimittel, further to its previous bid failing to gain adequate shareholder support. 11 July 2017
Pharmaceutical
French pharma major Sanofi is back on the takeover track, albeit not a mega bucks deal, announcing this morning that it will acquire Protein Sciences, a privately held US vaccines biotechnology company based in Meriden, Connecticut. 11 July 2017
Pharmaceutical
Events in the pharma sector hitting the headlines last week included a hitch for Merck & Co’s Keytruda, mixed results for Cara Therapeutics’ pain drug candidate CR848, Celgene’s deal with China’s BeiGene and an overview on the sluggish first-half 2017 M&A activity. 9 July 2017
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze